Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis by Bhasin, Madhuri et al.
BioMed  Central
Page 1 of 16
(page number not for citation purposes)
BMC Immunology
Open Access Research article
Modulation of microglial/macrophage activation by macrophage 
inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease 
course of experimental autoimmune encephalomyelitis
Madhuri Bhasin1, Muzhou Wu2 and Stella E Tsirka*1,2,3
Address: 1Genetics, Department of Pharmacological Sciences, University Medical Center at Stony Brook, Stony Brook, NY 11794-8651, USA, 
2Neuroscience, Department of Pharmacological Sciences, University Medical Center at Stony Brook, Stony Brook, NY 11794-8651, USA and 
3Molecular and Cellular Pharmacology, Department of Pharmacological Sciences, University Medical Center at Stony Brook, Stony Brook, NY 
11794-8651, USA
Email: Madhuri Bhasin - bhasin@pharm.stonybrook.edu; Muzhou Wu - muwu@ic.sunysb.edu; Stella E Tsirka* - stella@pharm.stonybrook.edu
* Corresponding author    
Abstract
Background: Myelin Oligodendrocyte Glycoprotein (MOG)-induced experimental autoimmune
encephalomyelitis (EAE) is the most commonly used mouse model for multiple sclerosis (MS).
During the of progression of EAE, microglia, the immunocompetent cells of the brain, become
activated and accumulate around demyelinated lesions. Microglial activation is mediated by the
extracellular protease tissue Plasminogen Activator (tPA), and mice lacking tPA display altered EAE
progression. In this study, we have used pharmacological inhibitors and stimulators of microglial/
macrophage activation to examine the temporal requirement for microglial activation in EAE
progression and to determine whether such approaches might potentially be of therapeutic value.
Results: Intervention using the tripeptide macrophage/microglia inhibitory factor MIF (TKP) and
the tetrapeptide macrophage/microglial stimulator tuftsin (TKPR) attenuated EAE symptoms and
revealed that the timing of macrophage/microglial activation is critical for the clinical outcome of
EAE. We show that the disease progression can potentially be manipulated favorably at early stages
by altering the timing of microglial activation, which in turn alters the systemic immune response
to favor upregulation of T helper cell 2 genes that promote recovery from EAE.
Conclusion:  Preventative and therapeutic modulation of macrophage/microglial activity
significantly alters the outcome of EAE at symptomatic stages. Specific molecular targets have been
identified that represent potential avenues of exploration for the treatment and prevention of MS.
Background
Multiple sclerosis (MS) is a central nervous system (CNS)
autoimmune disease with symptoms that include neuro-
logical impairment and motor deficits. MS results from
immune attack on myelin, which leads to axonal and neu-
ronal degeneration. A commonly used MS animal model
is experimental autoimmune encephalomyelitis (EAE).
EAE does not occur spontaneously, but does mimic some
of the pathological and histological hallmarks of MS. Dur-
ing EAE, T cells recognizing components of myelin
become activated, migrate to the CNS and cause autoim-
mune inflammation [1], which results in CNS infiltration
of CD4+, CD8+ T cells and B cells. The inflammatory
process includes secretion of proinflammatory T helper1
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(Th1) cytokines [2] and an imbalance between Th1, T
helper2 (Th2) and regulatory T cells [3,4]. When the ratio
of Th1 to Th2 cells favors a predominantly Th2 profile, the
proinflammatory properties of Th1 cytokines are coun-
tered and the severity of autoimmune diseases is allevi-
ated [5,6]. Administration of soluble Tim-2, which is
expressed preferentially by differentiated Th2 cells, to
mice prior to EAE induction, results in Th2 cytokine over-
production and EAE symptom amelioration [7]. Recently
another subclass of Th cells, the Th17, have been shown
to be involved in the modulation of EAE symptoms, act-
ing primarily through the cytokine IL-17 [8].
Microglia, which are macrophage-related cells resident in
the CNS, play crucial roles in CNS injury [9-11]. Tools to
study microglial involvement include pharmacologic
small molecules that stimulate or block their activation.
Tuftsin (threonine-lysine-proline-arginine, TKPR) pro-
motes phagocytic activity for cells of monocytic origin
that express tuftsin receptors, such as neutrophils, macro-
phages and microglia [12,13]. Tuftsin-positive cells are
recruited to sites of inflammation, and the avidity and
specificity of tuftsin for its receptor are sufficiently strong
to enable exploitation of tuftsin for imaging and thera-
peutic purposes [14-16].
MIF (the tripeptide threonine-lysine-proline, tuftsin frag-
ment 1–3, TKP) [17] inhibits macrophage/microglial acti-
vation by an unknown mechanism. In retrograde retinal
ganglion cell degeneration, MIF retards neuronal death,
enhances axonal regeneration, and elicits morphological
transformation of activated microglia into oval, less rami-
fied shapes [18]. MIF is an effective inhibitor of microglial
activation and neurodegeneration in the mouse hippoc-
ampus during episodes of excitotoxicity [19].
An endogenous factor that triggers microglial activation is
the serine protease tPA, which converts plasminogen into
plasmin. tPA activity increases ten-fold in MS lesions and
MS patients' cerebrospinal fluid during the acute disease
phase, but is not increased in chronic MS [20,21]. tPA
mRNA and activity increase in mice over the course of EAE
[22]. tPA's binding partner, annexin II [23] and the
remainder of the plasminogen activation system [24] are
also upregulated in MS lesions.
tPA-deficient (tPA-/-) mice display altered EAE course
compared to wild-type mice [22]. The onset of symptoms
is delayed, indicating a contribution of tPA to the disease
process; however, the extent of disease eventually exceeds
that observed in wild-type mice and lasts longer, revealing
an additional role for tPA in the recovery process. tPA is
critical for neuropathology in other model systems such
as excitotoxicity: tPA-/- mice are less susceptible to gluta-
mate-induced neurodegeneration in the hippocampus
[25]. Interestingly, early pharmacological blocking of
AMPA/KA glutamate receptors results in EAE ameliora-
tion, indicating that glutamate-induced excitotoxicity
contributes to EAE neurological malfunction [26,27].
Excitotoxicity is accompanied by microglial activation
and further glutamate release. A component of the com-
plex tPA role in EAE may include alterations in microglial
dynamics, since tPA-/- mice exhibit attenuated microglial
activation [25]. Supporting this hypothesis, active MS and
EAE lesions are characterized by activated microglia [28],
which have been shown to promote neurodegeneration in
systems that model ischemic episodes [29].
In this study, we examine the consequences of altering the
timing of macrophage/microglial activation during the
course of EAE, and show that manipulating this pathway
at the onset of clinical symptoms improves outcome,
potentially by promoting a bias towards a Th2 phenotype.
Results
Inhibition of microglial activation prior to EAE induction 
has only modest effects on EAE progression
Given that the role of both tPA and microglia in EAE
appears to be complex in nature, i.e. both degenerative
and protective mechanisms appear to operate, we elected
to examine the consequences of both microglial activa-
tion and microglial inhibition, and to do so at different
time points in the course of the disease.
We began by assessing the outcome of prophylactically
inhibiting microglial activation, i.e., administering an
activation inhibitor the day before the first injection of
MOG. For MOG-injected, PBS-treated (control) mice,
onset of EAE symptoms occurred at day 7 (d7) and pro-
gressively worsened until d21, after which the mice began
to recover (Fig. 1A). Prophylactic treatment with the mac-
rophage/microglial activation inhibitor MIF resulted in a
modest decrease in the rate of progression of the disease,
although the day of onset, ultimate severity and rate of
recovery were not dramatically different those observed
for the control mice.
Loss of myelination was evaluated at different time-
points. At d12, when the symptoms were still mild in
nature, the PBS-infused mice exhibited normal levels of
myelination (Fig. 1B). However, by d23, at which time the
height of severity of symptoms was reached, extensive
demyelination was apparent. Remyelination occured by
d30, in agreement with the decline of clinical disease
symptoms. In contrast, significant loss of myelination was
not observed at any time point in the MIF-infused mice,
consistent with the modestly improved clinical scores.
Macrophage/microglial activation was not detected in spi-
nal cord sections from PBS- or MIF-treated mice at orBMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
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Prophylactic MIF infusion does not alter onset, severity or recovery of EAE Figure 1
Prophylactic MIF infusion does not alter onset, severity or recovery of EAE. (A) Wt mice were infused with MIF for 
30 days, starting one day prior to EAE induction. The mice were weighed and scored daily for symptoms using the severity 
scale outlined in Methods. Daily scores were averaged. PBS n = 18; MIF d-1 n = 12. Wilcoxon test showed no statistically signif-
icant differences in onset, severity or recovery, but the progression of the disease is more delayed. (B) Frozen spinal cord sec-
tions were stained with Luxol Fast Blue to show areas of myelination. The dashed line and the asterisk demarcate the ventral 
column of the spinal cord. The intensity of luxol fast blue staining within the ventral column was quantified using the NIH Image 
freeware and was normalized to day 0 staining. Background staining was subtracted. (C) Immunohistochemistry for activated 
macrophage/microglial cells using F4/80 in frozen spinal cord sections. (D) Immunohistochemistry for infiltrating T cells using 
an anti-CD3 antibody.BMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
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before d12 (Fig. 1C). By day 23, however, many activated,
amoeboid macrophage/microglia were observed in the
PBS-treated mice, and, unexpectedly, significant activa-
tion was also seen in the MIF-treated mice. By day 30, the
macrophage/microglial activation had subsided in the
PBS-treated mice, in agreement with our previous reports
(Lu et al., 2002), and similar findings were observed for
the MIF-treated mice. In contrast, a slight reduction of
infiltration of T cells into the spinal cord may have
occurred for the MIF-treated animals as assessed by the T
cell marker CD3 (Fig 1D).
Taken together, a moderate improvement in clinical out-
come and demyelination was observed when the mice
were treated with MIF before MOG immunization,
despite the absence of complete inhibition of macro-
phage/microglial activation. Both morphological activa-
tion and migration to sites of injury are required for
microglia to carry out neurotoxic actions [30]; in this
instance, the clinical benefit observed may have ensued
from interfering more with the migration than with the
morphological activation.
Inhibition of microglial activation at EAE onset markedly 
decreases EAE progression
Given the modest improvement observed in Fig. 1 after
early intervention with MIF, an unexpectedly positive out-
come was obtained upon therapeutic use of MIF (initiat-
ing treatment at d7 after MOG injection), which elicited a
dramatic abrogation of EAE symptoms and complete
recovery by d27 (Fig. 2A). Histological decreases in mye-
lination (Fig. 2B) were not observed for the MIF-treated
animals, and, in contrast to what was observed for the
prophylactic treatment using MIF, macrophage/microglial
activation was also not observed (Fig. 2C), and there was
a more apparent reduction of infiltration of T cells into
the spinal cord (Fig. 2D). Multiple possibilities could
account for this difference in outcome, as presented in the
Discussion section.
Stimulation of macrophage/microglial activation before 
the onset of EAE in wild-type mice promotes low level EAE 
and earlier recovery from symptoms
The pharmacological manipulation of macrophage/
microglial status with MIF in the wt mice suggested that,
as in other paradigms [18], macrophage/microglia can
affect disease outcome and progress. Therefore, we sought
to determine the effect on EAE of prematurely activating
macrophage/microglia in wild-type mice.
Infusion of tuftsin one day prior to induction of EAE (tuf)
resulted in decreased symptom severity and earlier recov-
ery, although the day of onset was unaffected (Fig. 3A).
The symptoms plateaued at a low level (clinical score of 1)
before complete recovery was observed around day 29.
Significant demyelination in tuf-treated mice was evident
at d12 compared to the PBS-treated animals (Fig. 3B), but
remyelination occurred faster and was already detectable
at d23.
At day 12, while both PBS- and tuf-treated mice had sim-
ilar disease scores, the wt tufd-1 animals displayed strong
immunoreactivity for F4/80, the marker for microglial
activation (Fig. 3C). At later timepoints however, despite
the infusion of tuftsin, no macrophage/microglial activa-
tion was evident in wt tufd-1 compared to wt PBS mice.
The lack of macrophage/microglial activation was accom-
panied by virtual absence of CD3+ cells in the lesioned
spinal cord (Fig. 3D).
Stimulation of macrophage/microglial activation at the 
onset of EAE in wild-type mice attenuates EAE symptoms
Infusion of tuftsin in wild-type mice 7 days after MOG
immunization (tuf) resulted a dramatic attenuation of the
clinical symptoms (Fig. 4A). Minimal demyelination was
observed in tuf-treated mice at d12 (Fig. 4B), but the
demyelination increased by d23; however, by d30 the
remyelination process became evident and extended to
levels comparable to those in PBS-treated animals.
At day 12, tuf-treated mice showed little activated macro-
phage/microglial immunoreactivity (Fig. 4C). However
by day 23, a limited degree of macrophage/microglial acti-
vation observed. Very limited infiltration of CD3+ cells
was observed in the tuf-treated spinal cords at all time-
points (Fig 4D).
Early stimulation of macrophage/microglial activation in 
tPA-deficient mice accelerates the onset of EAE-like 
symptoms but prevents disease progression to severe levels
Since inhibiting macrophage/microglial activation in
wild-type animals at the onset of EAE symptoms
decreased the severity of disease, we next examined
whether provoking macrophage/microglial activation in a
setting where it is not maximal would exacerbate the pro-
gression of EAE. We used tPA-deficient animals, which
display attenuated activation of microglia in comparison
to wild-type animals in the context of excitotoxic and EAE-
elicited injury [25,22]. Tuftsin was employed to activate
macrophage/microglia in the animals prior to or during
the course of EAE.
Prophylactic administration of tuftsin to tPA-/-  mice
resulted in early onset (d3) of EAE-like symptoms (Fig.
5A) in comparison to PBS-treated wt mice (onset at day 7)
or tPA-/- mice (onset at day 10, data not shown). Despite
the early onset, however, a blunted disease progression
was observed, i.e. the symptoms never achieved the degree
of severity observed in PBS-treated mice.BMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
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Therapeutic MIF infusion severely abrogates the course of EAE Figure 2
Therapeutic MIF infusion severely abrogates the course of EAE. (A) No statistically significant difference was 
observed in EAE onset between wt PBS and wt MIFd7 mice. However, the symptom severity was dramatically decreased (p = 
0.0005) in wt MIFd7 compared to wt PBS; recovery was complete (p = 0.0005). wt PBS n = 18; wt MIF d7 n = 11. (B) Luxol 
Fast Blue staining shows very little demyelination at day 23 in wt MIFd7 mice. The dashed line and the asterisk demarcate the 
ventral column of the spinal cord. The intensity of luxol fast blue staining within the ventral column was quantified using the 
NIH Image freeware and was normalized to day 0 staining. Background staining was subtracted. (C) Immunohistochemistry for 
reactive macrophages/microglia using antibody against F4/80. (D) Immunohistochemistry for CD3+ T cells.BMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
Page 6 of 16
(page number not for citation purposes)
Prophylactic administration of Tuftsin in wild-type mice results in a dampened disease course Figure 3
Prophylactic administration of Tuftsin in wild-type mice results in a dampened disease course. (A) Disease onset 
in wt tufd-1 mice does not differ from wt PBS mice. Severity is dramatically decreased (p = 0.008) and recovery is complete (p 
= 0.016). wt PBS n= 18, wt tufd-1 n = 13. (B) Luxol fast blue histological stain reveals levels of myelination. The dashed line and 
the asterisk demarcate the ventral column of the spinal cord. The intensity of luxol fast blue staining within the ventral column 
was quantified using the NIH Image freeware and was normalized to day 0 staining. Background staining was subtracted. (C) 
Reactive macrophages/microglia are visible in the coronal sections of experimental mice at different timepoints. (D) Infiltrating 
T cells were detected by immunohistochemistry using an anti-CD3 antibody.BMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
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Therapeutic use of Tuftsin in wt mice results in a severely abrogated course of disease Figure 4
Therapeutic use of Tuftsin in wt mice results in a severely abrogated course of disease. (A) Disease onset is the 
same in wt tufd7 mice and wt PBS mice. Severity is strongly dampened (p = 0.004) and recovery is complete (p = 0.0002). wt 
PBS n= 18, wt tufd7 n = 13. (B) Levels of myelination are visualized using luxol fast blue. The dashed line and the asterisk 
demarcate the ventral column of the spinal cord. The intensity of luxol fast blue staining within the ventral column was quanti-
fied using the NIH Image freeware and was normalized to day 0 staining. Background staining was subtracted. (C) Macrophage/
microglial activation is visualized with F4/80 staining. (D) Immunohistochemistry for infiltrating T cells using an anti-CD3 anti-
body.BMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
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Prophylactic tuftsin infusion at day -1 in tPA-/- mice results in a dramatically early onset of EAE Figure 5
Prophylactic tuftsin infusion at day -1 in tPA-/- mice results in a dramatically early onset of EAE. (A) Disease 
onset occurs at day 3 in tPA-/- tufd-1 mice, much earlier than wt PBS (p = 0.03). Severity is dramatically decreased (p = 0.03) 
and recovery remained at a low level (p = 0.08). wt PBS n= 18, tPA-/- tufd-1 n = 11. (B) Luxol Fast Blue staining to visualize lev-
els of demyelination. The dashed line and the asterisk demarcate the ventral column of the spinal cord. The intensity of luxol 
fast blue staining within the ventral column was quantified using the NIH Image freeware and was normalized to day 0 staining. 
Background staining was subtracted. (C) F4/80 immunohistochemistry for activated macrophages/microglia. (D) Immunohisto-
chemistry for infiltrating T cells using an anti-CD3 antibody.BMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
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No loss of myelination was observed at d12 (Fig. 5B).
However, at the time-point with the most severe clinical
score, day 23, the tuftsin-treated mice showed low levels
of demyelination in the ventral column of the spinal cord,
though much less so than that observed in sections pre-
pared from wt mice treated with PBS. At day 30, there were
lingering low levels of demyelination in the tPA-/- tuftsin-
treated mice.
Macrophage/microglial activation, albeit limited, was vis-
ible in tPA-/- tuf-treated at d-1 mice as early as day 3 (Fig.
5C) and persisted for the duration of the period exam-
ined. However, the number of activated macrophages/
microglia observed at d23 and d30, while higher than that
observed for tPA-/- mice treated with PBS, was not as high
as that observed for wild-type. The number of infiltrating
CD3+ cells was also diminished in all timepoints for the
tPA-/- prophylactically treated with tuftsin (Fig. 5D).
Although the symptoms observed at day 2 appeared EAE-
like, it was possible that the tuftsin provoked an effect
unlinked to the MOG injection. To confirm that the symp-
toms were genuinely due to early onset EAE, we infused
tuftsin at d-1, and then injected complete Freund's adju-
vant and pertussis toxin with substitution of PBS for the
MOG. None of the mice exhibited any symptoms on the
EAE clinical score scale (data not shown), indicating that
the early onset of symptoms in the tPA-/- tuf-treated at day-
1 mice is dependent on the MOG immunization.
Stimulation of macrophage/microglial activation in tPA-
deficient mice as EAE symptoms start does not affect the 
course of EAE
Therapeutic use (day 7) of tuftsin in tPA-/- (tPA-/- tuf) mice
resulted in a disease pattern that was statistically similar to
the wild-type disease profile, with a similar day of onset,
day of peak severity, and course of recovery (Fig. 6A). Peak
severity was slightly lower in the tuftsin-treated animals,
but the difference was not statistically significant.
As we have previously reported [22], no loss of myelina-
tion levels is observed for MOG-injected wt or tPA-/- mice
at the d12 timepoint (Fig. 6B). Demyelination is observed
by d23 in wt mice ([22] and Fig. 1B), but is delayed in tPA-
/- mice with luxol fast blue (LFB) persistent loss being
observed at d30, by which time wt mice have remyeli-
nated. In contrast, readily detectable areas of demyelina-
tion were observed in the tPA-/- tuf mice at d12. At day 30,
when tPA-/- PBS mice still exhibit loss of myelination,
remyelination was detected in the tPA-/- tuf, mice similar
to wt PBS mice.
Levels of macrophage/microglial activation in tPA-/- tuf
mice were higher at day 12 than that observed for wild-
type mice treated with PBS (Fig. 6C). By day 23, both the
wt PBS-treated mice and the tPA-/- tuf-treated mice dis-
played robust and comparable levels of activated macro-
phage/microglia. In contrast, macrophage/microglia in
the tPA-/- mice treated with PBS exhibited only attenuated
activation. By day 30, the macrophage/microglia in wt
PBS-treated mice had begun to revert to a resting mor-
phology, but remained activated in the tPA-/- tuf-treated
mice. The numbers of CD3+ cells were comparable
between tPA-/- PBS and tPA-/- tuf animals, but were attenu-
ated in numbers in comparison to those found in wt PBS
mice (Fig 6D).
MIF and tuftsin decrease the activity of Angiotensin 
Converting Enzyme
Angiotensin Converting Enzyme or ACE catalyzes the con-
version of Angiotensin (Ang) I to Ang II. Ang II has been
implicated in inflammation [31] and the upregulation of
the expression of adhesion molecules thus influencing the
permeability of blood-brain barrier [32]. It has been
shown that administration of the ACE inhibitor captopril
(containing the dipeptide KP) has a beneficial effect on
EAE in Lewis rats [32]. Furthermore, tuftsin has been
shown to decrease functions of angiotensin II by 20%
[33]. Since MIF (TKP) and tuftsin (TKPR) differ by only
one amino acid at the tuftsin C-terminus, we sought to
determine whether MIF or tuftsin would function as an
ACE inhibitor. When ACE activity was quantified in the
presence of MIF or tuftsin, we found that MIF decreased
ACE activity by 33% and tuftsin inhibited ACE activity by
24% (data not shown). This result indicates that the two
compounds could function as ACE inhibitors to decrease
the systemic immune reaction, but does not address their
differential effect on the course of EAE.
A Th2 shift in the immune response
Differential expression of the transcription factors T-bet
and GATA-3 were used to analyze the Th1/Th2 balance in
EAE mice in all conditions, since T-bet controls the tran-
scription of Th1 markers and GATA-3 drives transcription
of Th2 markers. PBS-treated, MOG-injected wt and tPA-/-
mice were characterized by a strong Th1 response, indi-
cated by increasing levels of T-bet expression, and lowered
levels of GATA-3. This result is in agreement with reports
indicating that EAE is primarily a Th1-mediated disease
[34]. However, both MIF and tuftsin administration into
MOG-injected wt mice resulted in a shift towards
increased GATA-3 expression, indicating a switch to a Th2
response. Similarly, the infusion of tuftsin in tPA-/- mice
resulted in a strong Th2 response (Fig 7). These results
were further corroborated by measuring the expression
levels of Th1- (TNFalpha) and Th2- (IL10) specific
cytokines by RT-PCR and ELISA in spinal cord extracts
(data not shown).BMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
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Therapeutic administration of tuftsin in tPA-/- mice does not alter onset, severity or recovery of EAE Figure 6
Therapeutic administration of tuftsin in tPA-/- mice does not alter onset, severity or recovery of EAE. (A) Wil-
coxon test showed no significant difference in EAE parameters (p > 0.05). wt PBS n = 18, tPA-/- tufd7 n = 7. (B) Demyelination 
is visualized by luxol fast blue. The dashed line and the asterisk demarcate the ventral column of the spinal cord. The intensity 
of luxol fast blue staining within the ventral column was quantified using the NIH Image freeware and was normalized to day 0 
staining. Background staining was subtracted. (C) F4/80+-reactive macrophages/microglia detected by immunohistochemistry. 
(D) Immunohistochemistry for T cells using an anti-CD3 antibody.BMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
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Discussion and conclusion
The data presented n the current study indicate that
administration of macrophage/microglial modulators at
different points during the course of EAE can dramatically
affect the outcome of the disease. We used 4 different
modalities for modifying macrophage/microglial activa-
tion in MOG-injected wild-type mice, of which three
resulted in improved EAE clinical scores. MIF treatment as
EAE symptoms start, or tuftsin treatment either before or
at the time of symptom onset were effective, whereas pre-
treatment with MIF was of limited benefit. The complexity
of the disease does not readily allow us to offer a direct
explanation of the molecular events that underlie the dif-
ferences in disease outcome with the various modalities of
manipulations of microglial activation. One correlation
that connects the three successful modalities is the obser-
vation of a balanced T cell response with a predominance
of a Th2 fate for the activated T cells (Fig. 7). Another fac-
tor that could come into play is the requirement for mac-
rophages/microglia to migrate to local sites of injury. The
MIF macrophage/microglial inhibitor may block migra-
tion more effectively than morphological activation (Fig.
1), which could still confer a (modestly) beneficial out-
come, and accelerated activation by tuftsin might lead to
in situ morphological activation of the macrophages/
microglia than the usual chemotactic migration and pro-
liferation followed by local morphological activation.
This model would provide an explanation for why fewer
activated macrophages/microglia are observed after
tuftsin treatment in the areas of interest. Additional possi-
bilities are discussed below. Regardless, however, the ben-
efit of the intervention is clear.
In our previous work, we found that mice deficient in tPA
exhibit an altered progression of EAE symptoms that
included the timing of clinical disease onset and the
recovery from disease [22]. As these mice have attenuated
microglial activation, we explored the question here of
whether it was this deficiency that was driving the altered
EAE response by systemically delivering modulators of
macrophage/microglial activation and evaluating their
effect on the progression of EAE. Although using systemic
delivery is most relevant clinically, one concern about it is
whether the administered compounds reached the CNS in
therapeutic levels. Our data indicate that the compounds
delivered affected the status of cells in the CNS. Further-
more, when administering MIF/TUF prior to the induc-
tion of EAE, we observed in some cases dramatic effects
Quantification of T-bet (Th1 transcription factor) and GATA-3 (Th2 transcription factor) expression Figure 7
Quantification of T-bet (Th1 transcription factor) and GATA-3 (Th2 transcription factor) expression. Real time 
RT-PCR was performed on RNA from spinal cord homogenates extracted after the different treatments with MIF and tuftsin 
at various timepoints. Expression levels obtained for T-bet and GATA-3 were normalized against actin levels at the same time-
point in the same sample. #, denotes significant differences between the two (p < 0.05) groups for the specific treatment and 
timepoint.BMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
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very early on (for example in the case of tuftsin delivery at
day-1 in tPA-deficient animals), ostensibly before efficient
BBB breakdown.
Many treatments for MS have focused on controlling
blood-brain barrier permeability; inflammation is linked
to the opening of the blood-brain barrier, since it allows
infiltration of inflammatory cells into the CNS. Activated
microglia release cytokines and chemokines that draw
and activate leukocytes via the compromised blood-brain
barrier [35]. Numerous agents have been used that are
either anti-inflammatory themselves, or increase the
secretion of anti-inflammatory cytokines and decrease
that of pro-inflammatory cytokines [36].
The activation process of the endogenous microglia,
which converts them from resting ramified cells to immu-
nocompetent inflammatory ones, is associated with anti-
gen presentation, myelin and tissue breakdown,
production of reactive oxygen and nitrogen species and
pro-inflammatory cytokines [37,38]. In the absence of
activation, such as in the presence of an activation inhibi-
tor like MIF, microglia are unable to mediate these effects
[18]. The inhibition of microglial activation could thus be
responsible for the diminished demyelination observed
in the MIF-infused mice.
It is possible, on the other hand, that demyelination does
occur in the MIF-infused mice, albeit to a lower degree.
However, any myelin debris that is present might fail to be
cleared due to the absence of activated macrophages/
microglia. Consistent with this possibility, Luxol Fast Blue
would stain degradation products of myelin lipoproteins
that have not been phagocytosed by the inactivated mac-
rophages/microglia, thus explaining the increased LFB
staining despite the parallel symptomatology of MIF-
infused and PBS-infused wt mice. Therapeutic (day 7)
administration of MIF severely abrogated EAE symptoms.
Therefore, the timing of macrophage/microglial inhibi-
tion could therefore be crucial to the outcome of the dis-
ease. The absence of activated microglia at the onset of the
disease appears to have a beneficial effect.
Prophylactic activation of macrophages/microglia in tPA-
deficient mice, which normally exhibit attenuated micro-
glial activation [22], resulted in early onset of symptoms
at day 3 that persisted for the duration of the experiment.
Shaked et al., have shown in a model of optic nerve crush
injury that earlier onset of phagocytic activity and antigen
presentation by microglia results in resistance to injury
and neuronal survival [9]. It is possible that early activa-
tion of microglia could have ameliorated EAE in a similar
manner, by recruiting and interacting with the adaptive
immune response rather than worsening it, potentially
inducing protective autoimmunity.
Studies on protective autoimmunity have found that sys-
temic T-cell responses are triggered by injury to CNS
axons. The absence of mature T cells in some mouse
strains results in impaired CNS recovery [39]. Thus early
activation of microglia may have ameliorated the disease
by presenting antigen to T helper cells and subsequently
coordinating the resulting adaptive immune response. As
suggested by Shaked et al, the balance between protective
autoimmunity and autoimmune disease may be deter-
mined by the timing and intensity of microglial activation
and initial immune response [9]. The Th2, anti-inflamma-
tory switch that is evident in tPA-deficient mice after use
of tuftsin provides further support to the idea that tuftsin
may promote protective autoimmunity.
The protection conferred by early microglial activation
diminished when the activation was delayed. Tuftsin
administration at day 7 in tPA-/- mice resulted in a very
similar EAE course to that of PBS-infused mice. The thera-
peutic window for protection may be suboptimal when
microglia are activated late, as demonstrated by Shaked et
al. [9].
Our attempts to activate prematurely and in a sustained
manner wild-type microglia did not always result in
greater macrophage/microglial activation. In wt mice
infused with tuftsin at d-1, greater levels of macrophage/
microglial activation were observed at day 12 in compari-
son to wt PBS mice. However, when macrophage/micro-
glial activation in wt PBS mice is detectable, at day 23 and
day 30, the activation mediated by tuftsin seems to be
reversed and fewer activated macrophages/microglia are
observed (Fig 3C). This result suggests that there may be a
control mechanism that does not allow sustained superac-
tivation of macrophages/microglia. Despite the increased
reaction however, the EAE symptoms are dampened. It is
possible that macrophage/microglial activation during
the induction phase of EAE once again acts to protect (pre-
condition) against the disease. Once macrophage/micro-
glial activation is induced normally by the disease process,
tuftsin is no longer effective, potentially due to inability to
superactivate the cells. In that case, the therapeutic win-
dow has already been exploited in the early stages.
Tuftsin infusion in wild-type mice at the onset of disease
did not result in exaggerated macrophage/microglial acti-
vation at any timepoint (Fig 4C). Despite this result how-
ever, the disease course was severely abrogated. It is
possible that premature activation of macrophage/micro-
glial cells resulted in a paradoxical dampening of activa-
tion and reduced EAE intensity because of loss of antigen
presentation, myelin and tissue breakdown, reactive oxy-
gen species and pro-inflammatory cytokines, as men-
tioned above.BMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
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One explanation for the efficacy of MIF and tuftsin is that
they both act eventually as anti-inflammatory agents, as
they both can function as ACE inhibitors. Therefore in the
context of EAE this function could result in reduction of
inflammation and limited infiltration of immune cells
from the systemic circulation [31]. Indeed, in a model of
heart failure, it has been shown that ACE inhibitors
reduce the ratio of Th1 cytokines to Th2 cytokines, which
is indicative of a switch away from inflammation [40].
Furthermore, it has been shown that use of an ACE inhib-
itor, captopril, has a beneficial effect on EAE in Lewis rats
[32]. On the other hand, while it is true that MIF and
tuftsin may be acting as ACE inhibitors/anti-inflamma-
tory agents, this is not universally true, as shown in Figs. 1
and 4, where although the two compounds are delivered,
there is little change in EAE severity.
As the first line of defense in the CNS, microglia are critical
determinants of the outcome of local injury. The timing
and intensity of macrophage/microglial activation appear
to be crucial to the course of the disease. Whether this
effect is mediated by the interplay with T cells of the adap-
tive immune response and/or by modulation of inflam-
mation, this study suggests that careful modulation of
macrophage/microglial activation may be a viable thera-
peutic approach.
Methods
All work with mice was approved by the Department of
Laboratory Animal Resources at the State University of
New York at Stony Brook. Mice were maintained under
pathogen-free conditions at 21°C under a 12-hour light/
dark cycle. Access to food and water was ad libitum.
Induction of EAE
EAE was actively induced using myelin oligodendrocyte
glycoprotein (MOG) 35–55 (MEVGWYRSPFSRVVH-
LYRNGK), as previously described [22,41]. MOG 35–55
was synthesized by Quality Controlled Biochemicals and
purified using reverse-phase (C18) HPLC (QCB, Bio-
source, MA).
MOG35-55 (300 ug) was thoroughly homogenized with
Freund's Adjuvant (Sigma, St. Louis, MO) containing 500
ug  mycobacterium tuberculosis (Difco, Detroit, MI). This
emulsion (200 ul) was injected into the flank of female
mice (wild-type and tPA-/-), aged 6–10 weeks (day 0)
along with 500 ng of pertussis toxin (List Biological Labo-
ratories, Campbell, CA), which was injected ip in a vol-
ume of 200 ul. Two days later (day 2), the pertussis toxin
was injected for a second time. On day 7, a second MOG
injection was given in the opposite flank.
Evaluation of EAE symptoms
An experimenter blinded to treatment conditions and
genotypes monitored behavioral symptoms and weighed
the animals daily. Symptom severity was assessed on a
scale of 0 to 5 with intermediate scores being denoted by
graduations of 0.5. The scale is as follows: 0, no symp-
toms; 1, loss of tail tone; 2, wobbly gait; 3, hindlimb
paralysis; 4, forelimb paralysis; 5, moribund or dead [42].
Time-controlled drug delivery
Alzet miniosmotic pumps (Durect, Cupertino, CA) were
used to ensure time-controlled compound delivery. 14-
day pumps (rate of infusion 0.5 ul/hr, 200 ul total vol-
ume) were filled with either PBS, 500 uM MIF (Sigma, St.
Louis, MO) or 500 uM tuftsin (American Peptide Com-
pany, Sunnyvale, CA) and incubated overnight at 37°C,
according to manufacturer's instructions.
Adult wild-type and tPA-/- female mice (6–10 weeks old)
were deeply anesthetized using i.p. atropine (0.6 mg/kg
body weight) and 2.5% avertin (0.02 ml/g body weight).
Pumps were implanted subcutaneously in the back of the
animal for 14 days. Pumps were replaced at d14 with fresh
14-day pumps and were maintained for the duration of
the experiment. The pumps containing PBS were
implanted at the same time as the respective MIF and
tuftsin pumps.
In early control experiments we confirmed that placement
of a PBS pump either prior to (day -1) or after (day 7) EAE
induction did not alter the course of disease. Therefore, all
data for wild-type mice or tPA-/- mice infused with PBS
were pooled together from 4 independent experiments.
Importantly, wt- or tPA-/--PBS mice were used in every sin-
gle experiment and ran as controls side-by-side with the
experimental groups.
Immunohistochemistry and histological stains
Spinal cords were harvested from mice at various time-
points over the course of the disease, and were fixed in 4%
paraformaldehyde and 20% sucrose in PBS. The spinal
cords were divided in three equal sections. The sections of
each spinal cord were embedded in Tissue-Tek (Miles,
Elkhart, IN) optimal cutting temperature compound, fro-
zen on dry ice, and stored at -80°C until use. Coronal sec-
tions were obtained using a cryostat (Leica, Nussloch,
Germany) and mounted onto slides (Superfrost Plus,
Fisher Scientific), such that all three initial sections were
represented. Slides were stored at -80°C until use.
After inhibiting endogenous peroxidase activity using
0.3% hydrogen peroxide, sections were blocked with
serum overnight. F4/80, an antibody revealing macro-
phages/microglia, at 1:100 (Serotec, Raleigh, NC), was
added to the sections for 1 hr at room temperature [43].BMC Immunology 2007, 8:10 http://www.biomedcentral.com/1471-2172/8/10
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The sections were incubated with secondary antibody
(Vector Labs) for 1 hour at room temperature, the ABC
reagent (Vector Laboratories, Burlingame, CA) was added
and diaminobenzidine was applied for visualization of
the avidin-biotin complex [29]. Slides were then succes-
sively dehydrated, dipped in xylene and then coverslipped
using Permount (Fisher Scientific, Pittsburgh, PA). In
addition to F4/80 other markers were also used to visual-
izing the status of microglial activation, such as Isolectin
B4, Iba1, and 5-D-4 (data not shown).
To evaluate the levels of myelination of individual sec-
tions, slides were dehydrated and incubated overnight at
56°C in 0.1% Luxol Fast Blue (Sigma, St. Louis, MO) in
95% ethanol and glacial acetic acid. The slides were then
rinsed in 95% ethanol and distilled water and differenti-
ated successively in 0.1% lithium carbonate and 70% eth-
anol. After dehydration and xylene treatment, the slides
were coverslipped using Permount. The intensity of LFB
labeling was quantified on multiple sections in each ani-
mal and was averaged and plotted.
Angiotensin Converting Enzyme (ACE) assay
For the standard curve, varying volumes of 0.1 units/ml of
ACE were incubated with 200 ul of 6.25 mM hyppuric
acid (substrate) in 125 mM borate buffer. To test for inhi-
bition of ACE activity, varying volumes of 0.5 mM MIF or
Tuftsin were preincubated for 1 hour at room temperature
before adding 200 ul of substrate. All samples were incu-
bated with substrate for 90 minutes at 37°C in glass test
tubes. The reaction was stopped by addition of 250 ul of
20 mM EDTA in borate buffer. 2 ml of borate buffer and
1.5 ml of 160 mM cyanuric chloride (resuspended in spec-
trophotometric grade Dioxane) were added. Tubes were
centrifuged for 10 minutes at 6000×g. Absorbance of
supernatants was read in a spectrophotometer at 405 nm
against distilled water [44].
T-bet and Gata-3 quantitative RT-PCR
RNA was extracted from spinal cord homogenates using
Trizol (Invitrogen, CA). cDNA was synthesized using
SuperScript™ II Reverse Transcriptase (Invitrogen, CA) as
per the recommended protocol. Two μl of the diluted
cDNA was used in a 20-μl realtime PCR reaction volume
containing 3 mM MgCl2, 0.5 μM of each primer, and all
other components as recommended by LightCycler® Fast-
Start DNA Master SYBR Green I kit (Roche Applied Sci-
ence). The reactions were performed on LightCycler®
instrument (Roche Applied Science).
The primers used for PCR were:
T-bet (forward): GCCAGGGAACCGCTTATATG
T-bet (reverse): TCCCCCAAGCAGTTGACAGT
GATA3 (forward): CTGACTATGAAGAAAGAAGGCATC-
CAG
GATA3 (reverse): AAGTAGAAGGGGTCGGAGGAACTCT
β-Actin (forward): GGCCACTGCCGCATCCTCTT
β-Actin (reverse): AGAGCCTCAGGGCATCGGAAC
The PCR program for T-bet was 95°C for 10 min, then 40
cycles at 95°C (10 s), 62°C (5 s), and 72°C (20 s), fol-
lowed by the standard melting curve. The PCR program
for GATA3 was 95°C for 10 min, then 40 cycles at 95°C
(10 s), 58°C (5 s), and 72°C (20 s), followed by the
standard melting curve. The PCR program for β-Actin was
95°C for 10 min, then 45 cycles at 95°C (10 s), 65°C (5
s), and 72°C (5 s), followed by the standard melting
curve.
Statistics
All EAE graphs were analyzed using GraphPad Prism. The
Wilcoxon test for nonparametric data was performed to
compare differences between drug treatment and PBS
EAE. Statistical analysis was done for three EAE parame-
ters: onset, severity and recovery. Timepoints for analysis
were chosen based on first and last day of each of the
parameters for all mice in a set. Student's T-tests were per-
formed to compare myelination levels between the con-
trol and experimental group at each timepoint. P values
are listed on the relevant graphs.
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